AwiqliWhat to know
30-second read
For Pediatrics · Endocrinology
- Who
- Patients 10 to under 18 with type 2 diabetes already requiring basal insulin, as an adjunct to diet and exercise. Not approved for type 1 diabetes or children under 10.
- What’s new
- FDA extended Awiqli (insulin icodec-abae)’s adult label to age 10+ — the first once-weekly basal insulin for a pediatric population, announced 23 October 2026.
- Evidence
- Adult ONWARDS trial data plus one 18-patient single-dose pharmacokinetic study in ages 10–17. No dedicated pediatric efficacy trial was run.
- Big advantage
- Cuts basal injections from up to 365 a year to 52, in a population where daily-injection adherence is a well-documented problem through adolescence.
- Key consideration
- A ~196-hour (8-day) half-life: the same drug was rejected for type 1 diabetes in 2024 over hypoglycemia, and a wrong weekly dose can’t be corrected like a daily dose.
- Availability
- Approved for adults since March 2026. Adult savings program lists $35/month commercially insured; pediatric pricing and formulary status weren’t found in materials reviewed.
Practice impactConsider in selected adolescents
A genuine adherence option for a 10-to-17-year-old already established on daily basal insulin for type 2 diabetes — not a reason to start insulin earlier, or to bypass metformin and lifestyle therapy as the guideline-preferred first step.
FDA has extended Awiqli (insulin icodec-abae), Novo Nordisk’s once-weekly basal insulin, to patients as young as 10 with type 2 diabetes, the company said 23 October 2026 — the first once-weekly basal insulin labeled for a pediatric age group. The extension leans entirely on the adult record FDA accepted in March 2026 and a small pharmacokinetic study, not a new efficacy trial in children. It also arrives two years after the same molecule was turned away for a different population, on evidence a pediatric prescriber should understand before writing the first script.
A label extension, not a new trial
Insulin icodec is a basal insulin analog engineered for a week-long duration of action: reversible albumin binding and reduced insulin-receptor affinity slow its clearance enough that a single weekly injection covers the same ground as daily dosing. FDA approved it for adults with type 2 diabetes as Awiqli in March 2026, built on Novo Nordisk’s ONWARDS program. The 23 October action does not approve a new molecule or a new indication — it extends that existing adult type 2 diabetes label to patients 10 years and older, on the strength of the adult data already on file plus a single-dose pharmacokinetic study conducted specifically in 18 patients aged 10 to under 18.
That is a recognized FDA pathway — pediatric extrapolation, where a sponsor shows a drug behaves predictably (similar exposure, similar disease course) in children rather than repeating a full efficacy trial — and it is also a narrower evidentiary bar than the adult approval rested on. The label says so directly: safety and efficacy in children under 10 have not been established, because neither the adult trials nor the adolescent pharmacokinetic study extend to that younger group.
Why the 2024 rejection is the first thing worth knowing
Icodec is not a drug without a regulatory history, and the history matters here. FDA issued a complete response letter on Novo Nordisk’s original icodec application in July 2024, after an FDA advisory committee voted 7-4 in May 2024 against approval for type 1 diabetes. The committee’s objection traced to ONWARDS 6, the one trial in the ONWARDS program that enrolled patients with type 1 diabetes, comparing once-weekly icodec against once-daily degludec, both alongside mealtime insulin. Premeeting briefing documents flagged a higher rate of hypoglycemia with icodec in that trial; icodec still met its non-inferiority margin on HbA1c reduction, but the panel judged the benefit-risk balance in type 1 diabetes unfavorable given the added hypoglycemia.
The other five ONWARDS trials studied type 2 diabetes, and the advisory committee did not discuss type 2 use at that meeting. FDA approved Awiqli for adult type 2 diabetes in March 2026 once the manufacturing and labeling matters in the CRL were resolved. Icodec remains unapproved for type 1 diabetes in the U.S. today. Today’s pediatric extension inherits the type 2-only approval, not the type 1 rejection — but the hypoglycemia signal that sank the type 1 application is a reminder that this insulin’s long tail is not risk-free merely because the indication is different, a point worth carrying into any discussion of hypoglycemia monitoring in an adolescent who is active, inconsistently supervised around meals, or still learning to recognize her own symptoms.
Where Awiqli actually fits in pediatric T2D care
ISPAD’s 2024 consensus guideline and the ADA’s pediatric position are not displaced by this approval. Metformin remains the preferred first-line therapy for a metabolically stable patient with HbA1c under 8.5%. Insulin — daily basal insulin, specifically, in ISPAD’s guidance, at a starting dose of 0.25 to 0.5 units/kg — is reserved for patients who are ketotic or in diabetic ketoacidosis, markedly hyperglycemic at diagnosis, or whose type 1-versus-type 2 status is not yet clear. Awiqli does not move insulin earlier in that sequence. What it offers is a once-weekly alternative within the population that already needs basal insulin: a 10-to-17-year-old on daily glargine or degludec who is missing doses, or whose family is managing the injection burden around school and sports, is the plausible candidate population, not a newly diagnosed patient who would otherwise start on metformin alone.
The pediatric evidence, specifically
From FDA's pediatric approval announcement, 2024 advisory committee briefing documents, and trade coverage (Healio, Pharmacy Times, AJMC). FDA's public pediatric approval materials reviewed for this story did not specify a pediatric starting dose or titration schedule; confirm current dosing in Awiqli's full prescribing information before initiating a pediatric patient.
What an 8-day half-life changes at the bedside
A weekly insulin is not simply a daily insulin given less often. Icodec’s long half-life means it takes three to four weekly doses to reach a stable plateau, its glucose-lowering effect peaks days after the injection rather than hours, and a dosing error does not resolve the way a single wrong daily dose does — its effects are distributed and extended across the following week. That is the same structural feature that makes a weekly regimen attractive for adherence and awkward for acute management: there is no equivalent of holding a dose for a sick day, a missed meal, or a procedure, because the dose already given keeps acting regardless. Families and adolescent patients need to understand that before the first injection, not after a hypoglycemic episode explains it to them.
Coverage, and what is not yet established
Novo Nordisk's adult NovoCare savings program lists $35 a month for commercially insured patients and $55 a month for uninsured patients, with a stated $99 list price per package, according to company statements reported in trade coverage; those figures predate and do not specifically address the pediatric extension, and accumulator or maximizer insurance plans are excluded from the savings program. Early payer decisions on Awiqli generally have been mixed — at least one regional plan added it to a children's formulary this year, while another excluded it at launch pending review — which is consistent with a newly launched insulin rather than any pediatric-specific coverage signal. This desk found no FDA or company statement addressing pediatric-specific pricing, prior authorization, or formulary status as of this writing; confirm current coverage directly with the payer before counting on it for a specific patient.
- Patient selection is the gate. This extension adds a once-weekly option within the existing population needing basal insulin — not a reason to start insulin earlier or ahead of metformin in a stable, newly diagnosed adolescent.
- The evidence is extrapolated, not replicated. No pediatric efficacy trial backs this label; the pharmacokinetic study in 18 patients confirms exposure, not that the adult efficacy and safety profile transfers unchanged to a growing, more variably supervised patient.
- Hypoglycemia counseling deserves the same weight as the injection-count pitch. The drug's own 2024 type 1 diabetes rejection was a hypoglycemia finding; a slow-clearing weekly insulin in an adolescent managing sports, irregular meals and self-monitoring independence is not a population to under-counsel on recognizing lows.
- There is no mid-week correction. Unlike a daily basal dose, a miscalculated weekly dose keeps acting for days; confirm the family understands this before the first injection, not after an event.
- Confirm coverage per patient. Formulary status reads as unsettled this early in the pediatric launch; verify before relying on the adult savings-program figures for a specific prescription.
From a rejected type 1 application to a pediatric type 2 label
- May 2024
Advisory committee votes against type 1 use
7-4 vote against approval in type 1 diabetes, citing a hypoglycemia signal in ONWARDS 6.
- Jul 2024
Complete response letter
FDA declines to approve the original BLA, covering manufacturing and the type 1 diabetes indication.
- Mar 2026
Adult type 2 diabetes approval
FDA approves Awiqli for adults with type 2 diabetes, built on the type 2-focused ONWARDS trials.
- 23 Oct 2026
Pediatric extension to age 10+
FDA extends the adult type 2 diabetes label to patients 10 to under 18, on adult data plus an 18-patient PK study.
- Ahead
Pediatric dosing detail and formulary settling
Pediatric-specific starting-dose guidance and payer coverage decisions were not yet publicly detailed as of this writing.
Sources & further reading
- Healio, “FDA approves Awiqli, a once-weekly basal insulin for children with type 2 diabetes,” 23 October 2026. healio.com
- Pharmacy Times, “FDA Approves Awiqli, Once-Weekly Insulin for Children Aged 10 Years and Older With T2D.” pharmacytimes.com
- AJMC, “FDA Extends Once-Weekly Insulin to Youth With Type 2 Diabetes.” ajmc.com
- Contemporary Pediatrics, “FDA approves once-weekly insulin icodec for pediatric T2D,” 23 October 2026. contemporarypediatrics.com
- Drug Topics, “Novo Nordisk's Once-Weekly Insulin Faces Approval Setback With CRL,” 10 July 2024. drugtopics.com
- Managed Healthcare Executive, “FDA Issue CRL for Once-Weekly Insulin for Type 1 Diabetes,” 11 July 2024. managedhealthcareexecutive.com
- Managed Healthcare Executive, “Novo Nordisk Launches Awiqli, a Once-Weekly Basal Insulin,” 11 August 2026. managedhealthcareexecutive.com
Regulatory News reports on public regulatory documents. It is not legal advice, and the primary sources above govern. If we have made an error, we will say so in public: see corrections.
Frequently asked questions
Is this a new drug, or new evidence that children respond to icodec the way adults do?
Neither, strictly. FDA did not require a new pediatric efficacy trial. It accepted Awiqli's existing adult record from the ONWARDS program (five of six trials studied type 2 diabetes) plus a single-dose pharmacokinetic study in 18 patients aged 10 to under 18, confirming the drug behaves predictably in a younger body before extrapolating the adult efficacy findings down. Extrapolation is a recognized FDA pediatric pathway, not a shortcut unique to this drug, but it is a narrower evidentiary bar than a dedicated trial, and the label says so: safety and efficacy under age 10 are not established.
Why did the same drug get rejected in 2024?
FDA's July 2024 complete response letter followed a May 2024 advisory committee vote (7-4 against) on icodec's use in type 1 diabetes, where ONWARDS 6 showed a higher hypoglycemia signal versus daily degludec plus mealtime insulin. That trial, and the adcomm discussion, concerned type 1 diabetes specifically. Icodec's type 2 diabetes evidence was not the point of contention, and FDA approved Awiqli for adult type 2 diabetes in March 2026. Today's action extends that type 2-only approval down in age; it says nothing new about type 1 diabetes, where icodec remains unapproved in the U.S.
Does this change when a pediatric patient should start insulin?
No. ISPAD's and the ADA's pediatric guidance still reserve insulin at diagnosis for patients who are ketotic, markedly hyperglycemic, or whose type 1-versus-type 2 status is unclear; metformin remains first-line for a metabolically stable patient with HbA1c under 8.5%. Awiqli gives a once-weekly option within the existing population that already needs basal insulin — it does not move insulin earlier in the pediatric T2D treatment sequence.
